A Phase 1 Study of TRS005 in Patients With R/R CD20-positive B-NHL.

NCT ID: NCT05395533

Last Updated: 2025-06-25

Basic Information

• Recruitment Status: ACTIVE_NOT_RECRUITING
• Clinical Phase: PHASE1
• Total Enrollment: 147 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2020-09-08
• Study Completion Date: 2025-12-31

Brief Summary

This trial is a multicenter, open, single arm, dose increasing and extended clinical trial. The dose was increased according to the "3 + 3" rule. Patients with recurrent or refractory CD20 positive B-cell non-Hodgkin's lymphoma were selected to evaluate the safety, tolerance (DLT, MTD) and pharmacokinetic (PK) characteristics of TRS005 by intravenous drip.

Detailed Description

The subjects were screened and examined according to the protocol before enrollment. The dose of the enrolled subjects was increased according to the following 6 dose groups: 0.1mg/kg, 0.5mg/kg, 1.0mg/kg, 1.5mg/kg, 1.8mg/kg, 2.1mg/kg. The incremental process is divided into groups according to the principle of 3 + 3 dose increment. The subjects randomly receive intravenous drip of TRS005 in chronological order. Each subject first carries out a single dose study, and then carries out multiple continuous doses. The first dose is given once in D1. After 21 days of observation, it is decided whether to continue multiple continuous doses according to the situation. They are given once in C2D1, C3D1, C4D1, C5D1, C6D1, or more cycles respectively, and received treatment until progressive disease or unacceptable toxicity. During the dose escalation process, the investigators will perform dose expansion according to the clinical benefits of different dose groups.

Conditions

CD20-positive B-cell Non-Hodgkin Lymphoma

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Recombinant CD20 monoclonal antibody-MMAE conjugte for injection (TRS005)

To evaluate the safety and tolerability of TRS005 in patients with recurrent or refractory CD20-positive B-cell non-Hodgkin's lymphoma with treatment at one or more times, and to recommend the dose for phase II clinical trials (RP2D).

Group Type: EXPERIMENTAL

Recombinant CD20 monoclonal antibody-MMAE conjugte for injection

Intervention Type: DRUG

The dose of the enrolled subjects was increased according to the following 6 dose groups: 0.1mg/kg, 0.5mg/kg, 1.0mg/kg, 1.5mg/kg, 1.8mg/kg, and 2.1mg/kg.

Interventions

Recombinant CD20 monoclonal antibody-MMAE conjugte for injection

The dose of the enrolled subjects was increased according to the following 6 dose groups: 0.1mg/kg, 0.5mg/kg, 1.0mg/kg, 1.5mg/kg, 1.8mg/kg, and 2.1mg/kg.

Intervention Type: DRUG

Other Intervention Names

TRS005

Eligibility Criteria

Inclusion Criteria

1. Histologically confirmed CD20-positive B-cell non-Hodgkin lymphoma;

2. Relapse or refractory after receiving at least 2 standard treatment regimens;（Definition of refractory: Patients who did not reach PR in two cycles or CR in four cycles）;

3. At least 1 measurable tumor lesion, the maximum transverse diameter of the intranodal lesion should be > 1.5 cm and that of the extranodal lesion should be > 1.0 cm; CLL/SLL patients have treatment indications according to iwCLL 2018 guidelines;

4. Previously received anti-tumor treatment (such as radiotherapy, chemotherapy, hormone therapy, biotherapy, immunotherapy) at least 28 days before the first administration of this study; chemotherapy and hormono therapy should be at least 14 days before the first administration of this study; Chinese medicine anti-tumor treatment should be at least 7 days before the first administration of this study

5. The toxicity of previous anti-tumor treatment has been restored to ≤ grade 1 as defined by NCI-CTCAE v5.0 (except for alopecia; see Inclusion Criterion 6 for hemoglobin and renal function)；

6. The laboratory test results must meet the following requirements: (It is not allowed to give any blood components, short acting cell growth factor, albumin, etc., within 7 days before laboratory examination; long acting cell growth factor is not allowed to be given within the first 14 days):

• Hematology: Absolute neutrophil count (ANC) ≥ 1.5×109/L, platelets (PLT) ≥ 90×109/L, hemoglobin (HGB) ≥ 90 g/L;
• Liver function: Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 3 times the upper limit of normal, total bilirubin (TBIL) ≤ 1.5 times the upper limit of normal, (AST and/or ALT ≤ 5 times the upper limit of normal are allowed in patients with liver involvement);
• Renal function: Serum creatinine (Cr) ≤ 2 times the upper limit of normal;
• Coagulation function: (patients who have not received anticoagulant treatment before enrollment) International normalized ratio (INR) ≤ 1.5 times the upper limit of normal and activated partial thromboplastin time (APTT) ≤ 1.5 times the upper limit of normal;
• Pulmonary function test for patients with previous lung underlying disorders: measured/predicted value of vital capacity (VC) ≥ 60%, or diffusing capacity of the lungs for carbon monoxide (DLCO) ≥ 50% of predicted value;

7. ≥ 18 years , gender is not limited;

8. ECOG performance status 0-1;

9. Life expectancy of greater than 3 months;

10. Female and male patients of childbearing age and their spouses are willing to carry out adequate contraception throughout the study period, and female patients of childbearing age must have negative serum pregnancy test within 7 days before the first administration;

11. Patients voluntarily agree to participate in the study and to sign the informed consent form.

Exclusion Criteria

Patients who meet any of the following criteria will be excluded:

1. A clear history of drug allergy, and a history of ingredient allergy to heterogeneous proteins, biological agents or test drugs;

2. Active hepatitis B or C, or human immunodeficiency virus (HIV) antibody positive;

3. Those who are positive for syphilis antibodies and confirmed to be unresolved;

4. Tumor-infiltrating diseases of the central nervous system;

5. Accompanied by peripheral or central nervous system diseases;

6. Investigator-assessed diabetes uncontrolled by drug therapy;

7. Uncontrollable or symptomatic pleural/abdominal/pelvic effusion or pericardial effusion;

8. Patients with other malignancies within the past 5 years;

9. With active autoimmune diseases (such as systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, Sjogren's syndrome, autoimmune thrombocytopenia, etc.);

10. Accompanied by the following serious cardiovascular diseases or central nervous system diseases:

1. Myocardial infarction in nearly 6 months of screening period;

2. Unstable angina pectoris in the screening period of nearly 3 months;

3. Cardiac insufficiency (cardiac function grade ≥ NYHA class II);

4. Severe arrhythmia (e.g., persistent ventricular tachycardia, ventricular fibrillation);

5. Prolonged QTc interval (male > 450 ms, female > 470 ms);

6. Second or third degree heart block;

7. Drug-poorly controlled hypertension (systolic blood pressure > 160mmHg or diastolic blood pressure > 100mmHg);

8. Cerebrovascular accident (CVA) or transient ischemic attack (TIA), etc., within 6 months before the administration.

11. Other serious diseases, including but not limited to active peptic ulcer, active hemorrhage, venous thromboembolic event (VTE) and severe interstitial lung disease;

12. Accompanied by other serious diseases and serious active infections (such as pneumonia, active tuberculosis, etc.);

13. Received hematopoietic growth factor treatment within 1 week prior to first administration, including colony stimulating factor, interleukin or blood transfusion;

14. The dosage of steroid hormone (prednisone phase equivalent) used greater than 20mg/ day within 1 month prior to first administration for more than 14 consecutive days or immunosuppressive treatment;

15. Various vaccines were inoculated within 1 month prior to first administration;

16. Major surgery (except diagnostic biopsy) within 1 month prior to first administration;

17. Patients who received autologous stem cell transplantation within 2 months prior to first administration;

18. Patients who have received allogeneic stem cell transplantation in the past;

19. Patients with infusion reaction above grade III after previous monoclonal antibody treatment;

20. Participate in clinical trials of other drugs or medical devices within 1 month prior to first administration;

21. Patients previously treated with CAR-T;

22. Investigators assessed as unsuitable to participate in this study for other reasons.

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Zhejiang Teruisi Pharmaceutical Inc.

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Yuankai Shi, MD

Role: PRINCIPAL_INVESTIGATOR

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Locations

Chinese Academy of Medical Sciences, Cancer Hospital

Beijing, Beijing Municipality, China

Sun Yat-sen University Cancer Center (SYSUCC)

Guangzhou, Guangdong, China

Henan Cancer Hospital (Affiliated Cancer Hospital of Zhengzhou University)

Zhengzhou, Henan, China

The First Affiliated Hospital of Zhengzhou University

Zhengzhou, Henan, China

Second Affiliated Hospital of Soochow University

Suzhou, Jiangsu, China

Tianjin Medical University Cancer Institute & Hospital (TMUCIH)

Tianjin, Tianjin Municipality, China

Countries

China

Other Identifiers

TRS00501001

Identifier Type: -

Identifier Source: org_study_id